These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Inhibition of angiotensin-converting enzyme by derivatives of 3-mercapto-2-methylpropanoyl glycine. Schwab A; Weinryb I; Macerata R; Rogers W; Suh J; Khandwala A Biochem Pharmacol; 1983 Jun; 32(12):1957-60. PubMed ID: 6309188 [No Abstract] [Full Text] [Related]
63. Enharncement of the hemolytic activity of the second component of human complement by oxidation. Polley MJ; Müller-Eberhard HJ J Exp Med; 1967 Dec; 126(6):1013-25. PubMed ID: 4964564 [TBL] [Abstract][Full Text] [Related]
64. Effect of some phytogenic agents and synthetic compounds on complement cascade-mediated hemolysis. Rohde BH; Okawara T; Varma RS; Chiou GC Ophthalmic Res; 1994; 26(2):116-23. PubMed ID: 8196933 [TBL] [Abstract][Full Text] [Related]
65. Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the rabbit isolated heart from human complement-mediated damage. Gralinski MR; Wiater BC; Assenmacher AN; Lucchesi BR Immunopharmacology; 1996 Sep; 34(2-3):79-88. PubMed ID: 8886851 [TBL] [Abstract][Full Text] [Related]
66. Mechanism of the protective action of thiol compounds in ethanol-induced liver injury. Hirayama C; Kishimoto Y; Wakushima T; Murawaki Y Biochem Pharmacol; 1983 Jan; 32(2):321-5. PubMed ID: 6870960 [TBL] [Abstract][Full Text] [Related]
67. In vitro biotransformations of [14C]captopril in the blood of rats, dogs and humans. Wong KK; Lan S; Migdalof BH Biochem Pharmacol; 1981 Oct; 30(19):2643-50. PubMed ID: 7028042 [No Abstract] [Full Text] [Related]
68. The hemolytic activity of some trialkyltin and triphenyltin compounds. Byington KH; Yeh RY; Forte LR Toxicol Appl Pharmacol; 1974 Feb; 27(2):230-40. PubMed ID: 4854861 [No Abstract] [Full Text] [Related]
69. Adverse effects profile of sulfhydryl compounds in man. Jaffe IA Am J Med; 1986 Mar; 80(3):471-6. PubMed ID: 2937293 [TBL] [Abstract][Full Text] [Related]
70. New inhibitors of complement fixation. Lapidus M; Tomasco J Immunopharmacology; 1981 Jun; 3(2):137-45. PubMed ID: 6788728 [TBL] [Abstract][Full Text] [Related]
71. Immunochemical studies of hemoglobin and the role of the sulfhydryl groups. Atassi MZ; Brown RK; McEwan M Immunochemistry; 1965 Dec; 2(4):379-89. PubMed ID: 4957198 [No Abstract] [Full Text] [Related]
72. [STUDY ON THE USE OF THIOLA IN SKIN DISEASES]. TANIFUJI J; CHO Y Hifuka Kiyo; 1964 Nov; 59():301-7. PubMed ID: 14252545 [No Abstract] [Full Text] [Related]
73. [Role of sulfhydryl groups in myocardial contractions]. TURPAEV TM Biokhimiia; 1951; 16(6):611-4. PubMed ID: 14895535 [No Abstract] [Full Text] [Related]
74. [Inhibition and acceleration of roentgen hemolysis]. FLEMMING K Folia Haematol Int Mag Klin Morphol Blutforsch; 1960; 77():147-55. PubMed ID: 13823467 [No Abstract] [Full Text] [Related]
75. Ethylthio-formyl compound with antituberculous activity. IVANOVICS G; DUMBOVICH B Am Rev Tuberc; 1958 Jun; 77(6):1017-8. PubMed ID: 13533820 [No Abstract] [Full Text] [Related]
76. Effect of thallium on sulfhydryl compounds in vitro. FLESCH P; GOLDSTONE SB J Invest Dermatol; 1950 Nov; 15(5):345-7. PubMed ID: 14784607 [No Abstract] [Full Text] [Related]